🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Hengrui Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai Hengrui Pharmaceutical as lead sponsor. Synced 26 Sep 2026
27Current trials
22Recruiting now
27Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Hengrui Pharmaceutical is the lead sponsor of 27 current clinical trials in our China register. 22 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Adebrelimab, SHR-A2102 and Carboplatin. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting2281%
  • Not yet open27%
  • Active, closed311%

Trials by phase

  • Phase 1/21141%
  • Phase 1726%
  • Phase 2726%
  • Phase 327%
01

Clinical trials sponsored by Shanghai Hengrui Pharmaceutical

27 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
NCT06605222 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: SHR-7787
Phase 1/2 Recruiting 2024-10 China
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06589778 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 1/2 Recruiting 2024-09 China
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT06474455 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Recruiting 2024-07 China
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
NCT07490613 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 1 Recruiting 2026-06 China
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
NCT06108492 · ClinicalTrials.gov ↗ · Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Phase 1 Recruiting 2023-11 China
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
NCT06895928 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 2 Recruiting 2025-03 China
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
NCT05836948 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: SHR-9839
Phase 1 Recruiting 2023-05 China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
NCT06474468 · ClinicalTrials.gov ↗ · Advanced or Metastatic Esophageal Cancer
Phase 1/2 Recruiting 2024-06 China
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
NCT07073534 · ClinicalTrials.gov ↗ · Patients With Advanced or Metastatic Malignant Tumors
Phase 1/2 Recruiting 2025-07 China
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
NCT06738251 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma
Phase 3 Recruiting 2025-02 China
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
NCT06350006 · ClinicalTrials.gov ↗ · CLDN18.2-positive Advanced Solid Tumor
Phase 1 Recruiting 2024-05 China
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
NCT07268040 · ClinicalTrials.gov ↗ · Malignant Solid Tumors
Phase 2 Recruiting 2025-12 China
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
NCT06639347 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma
Phase 1/2 Recruiting 2024-11 China
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
NCT06654440 · ClinicalTrials.gov ↗ · Advanced Gynecological Malignancy
Drug: SHR-A2102
Phase 2 Recruiting 2024-11 China
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
NCT07229729 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 2 Recruiting 2025-11 China
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
NCT06417554 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Recruiting 2024-05 China
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
NCT07229586 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1/2 Recruiting 2025-12 China
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06649292 · ClinicalTrials.gov ↗ · Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3 Recruiting 2024-11 China
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: SHR-A2102
Phase 1 Recruiting 2023-04 China
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
NCT07296341 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Pancreatic Cancer With
Phase 1/2 Recruiting 2026-01 China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
NCT06512051 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/2 Recruiting 2024-07 China
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
NCT05410730 · ClinicalTrials.gov ↗ · High-risk NMIBC
Phase 1/2 Recruiting 2022-11 China
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT06704828 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: SHR-4602
Phase 2 Not yet open 2024-12 China
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
NCT07798947 · ClinicalTrials.gov ↗ · Limited-stage Small-cell Lung Cancer
Phase 2 Not yet open 2026-09 China
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
NCT04993430 · ClinicalTrials.gov ↗ · ER-Positive, HER2-Negative Breast Cancer
Phase 1 Active, closed 2021-10 China
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
NCT04877717 · ClinicalTrials.gov ↗ · Advanced Solid Cancer
Drug: SHR-A1904
Phase 1 Active, closed 2021-07 China
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
NCT05593250 · ClinicalTrials.gov ↗ · Asthma
Phase 2 Active, closed 2023-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Hengrui Pharmaceutical trials

27 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Hengrui Pharmaceutical trials

21 conditions
Advanced Solid Tumors6Advanced Urothelial Carcinoma2ER-Positive, HER2-Negative Breast Cancer1Non-Small Cell Lung Cancer1Multiple Myeloma1Intermediate and High-risk Non-muscle Invasive Bladder Cancer1Advanced Solid Tumor1Advanced or Metastatic Esophageal Cancer1Patients With Advanced or Metastatic Malignant Tumors1CLDN18.2-positive Advanced Solid Tumor1Malignant Solid Tumors1Advanced Gynecological Malignancy1Non-small Cell Lung Cancer1Advanced Solid Cancer1Solid Tumor1Asthma1Limited-stage Small-cell Lung Cancer1Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma1Locally Advanced or Metastatic Pancreatic Cancer With1Advanced or Metastatic Non-small Cell Lung Cancer1High-risk NMIBC1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2722

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Bristol-Myers Squibb5
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Hansoh BioMedical R&D Company4
Bayer3
Vividion Therapeutics3
Multitude Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Hengrui Pharmaceutical trials

How many clinical trials does Shanghai Hengrui Pharmaceutical sponsor?

Shanghai Hengrui Pharmaceutical is the lead sponsor of 27 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Hengrui Pharmaceutical trials recruiting?

Yes. 22 of its 27 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Hengrui Pharmaceutical testing?

Its current trials name 27 drugs and biologicals as interventions. The most frequent are Adebrelimab (12), SHR-A2102 (9), Carboplatin (4), Paclitaxel (4) and SHR-7787 (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.